ZYME:NASDAQ
Zymeworks Inc
US$27,94
arrow_downward
-2,17%(-0,62) 1 HR
US$28,20
arrow_upward
+0,93% (+0,26)bedtimeSetelah jam perdagangan normal
Tutup: 28 Apr, 16.00.00 GMT-4 · USD
search
Semua simbol
1 HR
5 HR
1BLN
6BLN
YTD
1THN
5THN
MAKS
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk ZYME...
Buka
US$28,61
Tinggi
US$28,88
Rendah
US$27,92
Kapitalisasi pasar
2,06 M
Volume rata-rata
637,00 rb
Volume
421,47 rb
Harga tinggi dalam 52 minggu terakhir
US$28,88
Harga rendah dalam 52 minggu terakhir
US$10,88
EPS
-US$1,08
Beta
1,20
Saham beredar
73,75 jt
Jumlah karyawan
264
Artikel berita
Dari berbagai sumber di seluruh web
Investing.com
·
16 jam yang lalu
H.C. Wainwright reiterates Zymeworks stock rating on FDA filing
MarketBeat
·
19 jam yang lalu
Zymeworks (NASDAQ:ZYME) Hits New 52-Week High - Time to Buy?
Simply Wall Street
·
1 hari yang lalu
April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value
Profil
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
Tentang Zymeworks Inc
CEOKenneth Galbraith
Karyawan264
Didirikan2003
Kantor PusatMiddletown, Delaware, Amerika Serikat
Sektor-
Situszymeworks.com
Konten AI mungkin berisi kesalahan. Pelajari lebih lanjut